Celgene Clinical Trials. Showing 3 of 1,300+ results. The RENEW Study—A clinical tri
Showing 3 of 1,300+ results. The RENEW Study—A clinical trial evaluating a study drug to see if it may safely and effectively reduce the need for anemia-related blood transfusions because Looking for answers? Clinical Trial information for researchers Clinical trials and research are a critical part of bringing new medicines to Celgene has posted data from a pivotal trial of its CAR-T therapy. The data look competitive against Gilead’s Yescarta and Novartis’ Kymriah, leading As part of its Celgene takeover Bristol Myers Squibb inherited a pipeline of “celmod” molecules designed to help weather Revlimid’s patent The rationale for the removal of the requirement to enroll at least 25% of subjects with an endogenous sEPO level of > 200 U/L stems from the observation of subject recruitment in this study and current By my signature, I agree to personally supervise the conduct of this study at my study site and to ensure its conduct is in compliance with the protocol, informed consent, Institutional Review Board . Celgene and bluebird bio have reported positive interim results from the ongoing trial of bb2121 to treat patients with multiple myeloma. Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evaluate the efficacy and safety of CC- The ongoing study could significantly impact Celgene’s stock performance, as positive results may enhance its market position in the oncology sector. Understand key factors to consider before deciding and get questions to ask your healthcare team. Study to Evaluate the Efficacy and Safety of Fedratinib in Combination with CC-486 in Patients Suffering from Myelofibrosis in Acute GlobalData’s premium database of Celgene Corp Clinical Trials helps in determining Celgene Corp’s go-to-market proposition and gaining insight into the company’s clinical operations, recruitment, and trial Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy. Bristol Myers Squibb fully supports the principles of enhanced transparency by sharing data from clinical trials on our approved medicines with qualified researchers. This randomized clinical trial evaluates the efficacy and safety of cendakimab compared with placebo in patients with moderate to severe atopic Explore Celgene International SARL with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, 5 news, and 1 literature, Disease Domain:Immune System Diseases, Explore Celgene Cellular Therapeutics with its drug pipeline, therapeutic area, technology platform, 6 news, and 1 literature, Drug:TST-001(Celgene Cellular), Cenplacel-L (Celularity). The trial is designed as a Phase 2, open-label, single-arm rollover study, aiming to evaluate the long-term safety and potential clinical benefits of CC-486 in subjects with hematological With a significant new product to trial and a partnering contract research organisation (CRO) on board, our client’s European clinical operations team faced a daunting task in getting a robust trial up and A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of Orally Administered BMS-986368, a FAAH/MAGL [Translation] A randomized, double-blind, multicenter phase III clinical study comparing the efficacy and safety of lenalidomide and placebo combined with R-CHOP in subjects with newly The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic By my signature, I agree to supervise and oversee the conduct of of this this study stu d and to ensure its conduct is in compliance with the protocol, informed med consent, consen ,1)2 IRB/EC AstraZeneca and MedImmune, its global biologics research and development arm, have been informed by partner Celgene that the US Food and Drug Administration (FDA) has placed a ICH GCP US Clinical Trials Registry Clinical Trial NCT06764485 A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Celgene has announced that the Phase III trial of CC-486 as maintenance therapy for acute myeloid leukaemia (AML) met primary and key secondary endpoints. Investors should monitor updates In a prior Phase I/II clinical trial, the oral BET inhibitor INCB057643, tested both as a monotherapy and in combination with ruxolitinib, demonstrated Celgene is also actively engaged in clinical trials, working with leading researchers and institutions to advance the science of medicine and improve patient outcomes. ICH GCP US Clinical Trials Registry Clinical Trial NCT03783403 A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic A Phase 2, Open-label, Single Arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin The clinical trial is a Phase 2, open-label, single-arm rollover study designed to evaluate the long-term safety of CC-486 in participants with hematological disorders who have previously Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Determine Celgene Corp go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.